8 results about "Hepatic portal" patented technology

The invention relates to a porta fibroplaque recognition device, method and equipment, a medium and a program product, and the device comprises an ultrasonic image collection module which is used for transmitting high-frame-rate plane wave ultrasound to a porta hepatis and generating an ultrasonic image based on an echo signal; the portal fibroplaque candidate region positioning module is used for preliminarily dividing the ultrasonic image to obtain a portal fibroplaque candidate region; the porta hepatis fibroplaque region identification module is used for further dividing to obtain porta hepatis fibroplaque regions; the multi-modal quantization parameter extraction module is used for extracting a quantization parameter set from the ultrasonic image based on the porta hepatis fibroplaque region; and the recognition result generation module is used for comprehensively analyzing the quantization parameter set and preset diagnosis reference information, and generating and outputting a porta hepatis fibroplaque recognition result. According to the method, high dependence on personal experience on porta fibroplaque recognition is converted into an objective, quantitative, standardized and efficient automatic auxiliary recognition process, and the recognition accuracy and consistency are improved.

The invention belongs to the technical field of biological medicine, and discloses a portal cholangiocarcinoma postoperative risk prediction model based on a gamma-glutamyltransferase (GGT) dynamic change track and a construction method thereof. The method comprises the following steps: (1) collecting clinical characteristic data and survival characteristic data (including survival time and survival state) of a patient suffering from porta hepatis cholangiocarcinoma subjected to radical resection; 2) on the basis of GGT detection results at different time points in a perioperative period, dividing patients into different GGT dynamic change track types by using a latent category hybrid model; and 3) taking the clinical characteristic data and the GGT dynamic change track type as independent variables, taking survival data as response variables, screening prediction factors through LASSO regression, and constructing a multi-factor Cox regression model, namely a postoperative risk prediction model. According to the method, the dynamic evolution rule of the GGT is introduced, so that the limitation of single-time static detection is made up, the quantitative evaluation of the survival risk is realized, and a scientific basis is provided for individualized treatment and follow-up visit management.

The invention relates to a pair of hepatic portal blocking forceps. After the nitrided stainless steel hepatic portal blocking clamp is subjected to vacuum annealing, the cooling rate greatly affects the corrosion resistance of the stainless steel hepatic portal blocking clamp. Researches show that when the cooling rate is 2.5 DEG C / min-6. 3 DEG C / min, the self-corrosion current density of the hepatic portal occlusion clamp can be lower than 2 [mu] A.cm <-2 >, and the service life of the hepatic portal occlusion clamp is remarkably prolonged.

The application discloses a focused ultrasound stimulation system and a control method for regulating liver metabolism, and the system comprises a focused ultrasound transducer, a robot positioning module, an image navigation module and a control module. The image navigation module acquires an ultrasound image of a target region, identifies feature points of a hepatic portal region and generates target point coordinates. The robot positioning module carries and moves the focused ultrasound transducer. The control module controls the robot positioning module to dynamically move the focused ultrasound transducer according to the real-time updated target point coordinates, so that the focal domain of the focused ultrasound transducer coincides with the target region, and controls the focused ultrasound transducer to output low-intensity focused ultrasound. The application also provides application of low-intensity focused ultrasound in preparation of a device for treating non-alcoholic fatty liver disease. The system realizes non-invasive physical regulation of liver metabolism, effectively improves lipid deposition and inflammation state, and has the advantages of automation, precision and repeatability.

The utility model relates to medical instrument technical field discloses a visible pressure's blood vessel blocking belt, including blocking belt main part, blocking belt main part one end fixedly connected with visible pipe section, the other end fixedly connected with the plug -in head of visible pipe section, the periphery of visible pipe section is equipped with the observation slot of opening, the pressure measurement component is set up between blocking belt main part outer surface and the inside of visible pipe section. In the utility model, through pressure measurement component, utilize the first water bag of blocking belt main part outer surface soft glue transparent capsule structure to paste and bind the blood vessel of liver portal department liver blood flow, under the binding effect, the colored measurement liquid in the first water bag passes the connecting pipeline and enters the second water bag with the measurement scale, and medical staff can observe and judge the blocking belt binding pressure through the observation slot of visible pipe section, so that can select different blocking pressure according to different case types, and further satisfy more individualized, fine operation demand.

This utility model discloses a hepatic hilum occlusion band, relating to the technical field of medical auxiliary equipment. The utility model includes an elastic band and a ring. The elastic band has multiple pairs of evenly arranged symmetrical slots on both sides. The ring is a rigid rubber ring, with corresponding grooves at both ends. A clamping structure is installed in one or more of the grooves. By designing multiple pairs of evenly arranged symmetrical slots and clamping structures, this utility model allows for adjustment of the tightness and size of the occlusion band's opening, making it easy to adjust and adaptable to blood vessels of different diameters. This makes the hepatic hilum occlusion band suitable for various surgical scenarios. When the spring and clamping plate are used in conjunction with a pair of pull rings, it not only facilitates clamping but also allows for quick and easy release of the hepatic hilum occlusion band after surgery, reducing postoperative complications. This device is compact, simple to operate, and easy to use for both blocking and releasing the hepatic hilum.

The utility model relates to a medical blood flow blocking belt related technical field, concretely is a simple and easy self -locking type hepatic portal blood flow blocking belt, including blocking belt end, blocking extension belt and through hole and self -locking component, the blocking extension belt is fixedly connected with the blocking belt end on the broken belt extension place, the blocking extension belt one end on the self -locking component is equipped with the through hole, the blocking belt end and the blocking extension belt can be bent through the inside elastic clamping self -locking of through hole, in the utility model, after the blocking belt end and the through hole blocking belt pass through the inside of through hole, make the blocking self -locking belt elastic extrusion deformation pass through the inside of through hole, the elastic band and the elastic band can be elastically wrapped in the blocking self -locking belt outside and carry out blood flow blocking belt self -locking, the blocking self -locking belt on the blocking belt end is wrapped on the hepatic portal, and the blocking self -locking belt is bent and is locked on the liver, carries out the blocking, avoids the liver blood flow too much, and the blocking self -locking belt is timely and fast self -locking blood flow blocking when the venous hemorrhage in the liver resection.

The invention discloses application of L-serine in prevention and / or treatment of cholestatic liver diseases. A cholestatic liver injury model induced by 0.1% DDC diet is given to a C57BL / 6J mouse, intervention is carried out for two weeks by adding or not adding 3% or 9% (w / w) of L-serine in diet, and it is proved from the animal experiment level that L-serine has a remarkable protection effect on cholestatic liver injury. Experimental results show that the levels of ALT, AST, TBA and Tbil in serum can be remarkably reduced through L-serine intervention; liver histopathologic analysis further shows that the L-serine can effectively relieve inflammatory cell infiltration, hepatic cell necrosis, cholestasis, bile duct hyperplasia and the fibrosis degree of a convergent duct region. In conclusion, L-serine provides a new strategy which is safe, effective, clear in effect and good in application prospect for preventing and treating cholestatic liver diseases.